ONCONasdaqPharmaceutical PreparationsFiscal year ends December 31
Onconetix, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.43−0.05 (-10.13%)
Close on Oct 19, 2026
- Market cap
- $965.06K
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$168.5697 (−99.75%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Split
Onconetix, Inc. saw revenue fall 51.3% to $645.82K over the twelve months to Jun 30, 2026.
Revenue
$645.82K
-51.3% vs. a year earlier
Operating income
-$16.31M
TTM Q2 2026
EPS, diluted
-$16.56
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $965.06K
- P/E ratio
- –
- Price to sales
- 1.49
- Price to book
- 0.07
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $645.82K
- Net income
- -$10.20M
- EPS, diluted
- -$16.56
- Book value per share
- $6.01
- Diluted shares
- 2M
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
$645.82K-51.3% YoY
Gross profit
$519.23K-41.1% YoY
Operating income
-$16.31M
Net income
-$10.20M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months